ClinConnect ClinConnect Logo
Search / Trial NCT06226883

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Launched by MORPHIC THERAPEUTIC, INC. (A WHOLLY OWNED SUBSIDIARY OF ELI LILLY AND COMPANY) · Jan 17, 2024

Trial Information

Current as of August 22, 2025

Recruiting

Keywords

Crohn's Disease (Cd) Inflammatory Bowel Disease (Ibd) A4b7 Moderate To Severe Integrin Garnet

ClinConnect Summary

This clinical trial is studying a new medication called MORF-057 to see how well it works and how safe it is for adults with moderately to severely active Crohn's disease, which is a condition that causes inflammation in the digestive tract. The study involves comparing the effects of MORF-057 with a placebo (a treatment that does not contain the active drug) to understand its potential benefits. The trial is currently recruiting participants aged 18 to 80 who have been experiencing symptoms of Crohn's disease for at least three months and have had limited success with other treatments.

To participate, individuals need to have a specific score that shows their Crohn's disease is active, and they should have tried at least one other treatment without getting better. Participants will need to attend regular study visits and follow certain guidelines throughout the trial. It's important for those interested to know that they cannot have certain other health conditions or have previously received specific treatments that could affect their eligibility. This study aims to help improve treatment options for Crohn's disease, and participants will play a vital role in advancing our understanding of this condition.

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • Has signs/symptoms of CD for at least 3 months prior to Screening
  • Has a CDAI score of 220 to 450, with an average daily stool subscore ≥4 points and/or an average daily abdominal pain subscore of ≥2 points
  • Has an SES-CD score of ≥6 (or an SES-CD score of ≥4 if CD is isolated to the ileum)
  • Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: Corticosteroids, Immunosuppressants (eg, azathioprine, 6-mercaptopurine, methotrexate) and/or advanced therapies for CD (eg, biologic agents, Janus kinase \[JAK\] inhibitors, applicable investigational products)
  • Agrees to abide by the study guidelines and requirements
  • Capable of giving signed informed consent
  • Key Exclusion Criteria:
  • Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or UC, or has clinical findings suggestive of UC
  • Has CD that is isolated to the oral cavity, stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement
  • Has had extensive bowel resection (\>100 cm), and/or more than 3 resections, and/or has a known diagnosis of short bowel syndrome
  • Is currently receiving total parenteral nutrition, tube feeding, or a formula diet
  • Has positive findings on a subjective neurological screening questionnaire
  • Has a concurrent, clinically significant, serious, unstable comorbidity
  • Previous treatment with vedolizumab or other licensed or investigational integrin inhibitors
  • Is currently participating in any other interventional study or has received any investigational therapy within 30 days
  • Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057
  • Unable to attend study visits or comply with study procedures

About Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary Of Eli Lilly And Company)

Morphic Therapeutic, Inc., a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage biotechnology firm focused on the discovery and development of innovative small-molecule therapeutics targeting integrins. Leveraging proprietary chemistry and biology platforms, Morphic aims to address unmet medical needs in areas such as fibrosis, oncology, and autoimmune diseases, advancing novel treatments through rigorous clinical development.

Locations

Madrid, , Spain

Montreal, Quebec, Canada

Houston, Texas, United States

Raleigh, North Carolina, United States

Bologna, , Italy

Lleida, , Spain

Bucharest, , Romania

Heidelberg, , Germany

Budapest, , Hungary

Vienna, , Austria

Sevilla, , Spain

Milano, , Italy

Calgary, Alberta, Canada

Kragujevac, , Serbia

Vaughan, Ontario, Canada

Kiel, , Germany

Belgrade, , Serbia

Jaipur, Rajasthan, India

Majadahonda, , Spain

Kochi, Kerala, India

Novi Sad, , Serbia

Sopot, , Poland

Tyler, Texas, United States

Pune, , India

Uzice, , Serbia

Liepaja, , Latvia

Roma, Lazio, Italy

San Giovanni Rotondo, Fg, Italy

Szczecin, , Poland

Rajkot, Gujarat, India

Zadar, , Croatia

Tbilisi, , Georgia

Dachau, , Germany

Salzburg, , Austria

Ulm, Baden Wuerttemberg, Germany

Shreveport, Louisiana, United States

Zrenjanin, , Serbia

Tbilisi, , Georgia

Valencia, , Spain

Leskovac, , Serbia

Halle, , Germany

Elblag, , Poland

Lynchburg, Virginia, United States

San Donato Milanese, Milano, Italy

Vandoeuvre Les Nancy, , France

Secunderabad, Andhra Pradesh, India

Bekescsaba, , Hungary

Szekszard, , Hungary

Presova, , Slovakia

Santo Andre, Sao Paulo, Brazil

Belgrade, , Serbia

Presov, , Slovakia

Bratislava, , Slovakia

Lancaster, California, United States

Cali, Valle Del Cauca, Colombia

Houston, Texas, United States

Berlin, , Germany

Madrid, , Spain

Valencia, , Spain

Ogden, Utah, United States

Kosice, , Slovakia

Bologna, , Italy

Wroclaw, , Poland

Karaganda, , Kazakhstan

Riga, , Latvia

Kissimmee, Florida, United States

Quebec, , Canada

Bydgoszcz, , Poland

Elblag, , Poland

Katowice, , Poland

Tychy, , Poland

Brasília, , Brazil

Lancaster, California, United States

Lynchburg, Virginia, United States

St. Poelten, , Austria

Cedar Park, Texas, United States

Tbilisi, , Georgia

Tbilisi, , Georgia

Ulm, , Germany

Milan, , Italy

Sopot, , Poland

Brno, , Czechia

Berlin, , Germany

São Paulo, , Brazil

Saint Etienne Cedex 02, , France

Eger, Heves, Hungary

Rozzano, , Italy

Zagreb, Grad Zagreb, Croatia

Warszawa, Mazowieckie, Poland

Warsaw, Mazowieckie, Poland

Opole, , Poland

Belgrade, , Serbia

Tyler, Texas, United States

Semey, , Kazakhstan

Shreveport, Louisiana, United States

Summerville, South Carolina, United States

Johnson City, Tennessee, United States

Batumi, , Georgia

Tbilisi, , Georgia

Ogden, Utah, United States

Warsaw, , Poland

Vienna, , Austria

Prague, , Czechia

Saint Priest En Jarez, , France

Heidelberg, Baden Wuerttemberg, Germany

Gyongyos, , Hungary

Szekesfehervar, , Hungary

Jaipur, Rajasthan, India

Milan, , Italy

San Giovanni Rotondo, , Italy

Riga, , Latvia

Elbląg, , Poland

Opole, , Poland

Poznan, , Poland

Szczecin, , Poland

Warsaw, , Poland

Zrenjanin, , Serbia

Bratislava, , Slovakia

Raleigh, North Carolina, United States

Tbilisi, , Georgia

Gdańsk, Pomorskie, Poland

Osijek, , Croatia

Zadar, , Croatia

Dachau, , Germany

Duisburg, , Germany

Budapest, , Hungary

Szekszárd, , Hungary

Rozzano, , Italy

Wroclaw, , Poland

Bucharest, , Romania

Kosice, , Slovakia

Presov, , Slovakia

Lleida, , Spain

Madrid, , Spain

Seville, , Spain

Innsbruck, , Austria

Brno, , Czechia

Negrar, , Italy

Czestochowa, , Poland

Warsaw, , Poland

Timişoara, , Romania

Belgrade, , Serbia

Kiel, , Germany

Kraków, , Poland

Calgary, , Canada

St. Poelten, , Austria

Virovitica, , Croatia

Pierre Benite, , France

Wipperfurth, , Germany

Gdansk, , Poland

Katowice, , Poland

Constanta, , Romania

Brno, , Czech Republic

Prague, , Czech Republic

Leskovac, , Serbia

Novi Sad, , Serbia

Southlake, Texas, United States

Montreal, , Canada

Toronto, , Canada

Vandoeuvre Les Nancy, , France

Halifax, , Canada

Eger, , Hungary

San Donato Milanese, , Italy

Bydgoszcz, , Poland

Kragujevac, , Serbia

Uzice, , Serbia

A Coruna, , Spain

Leon, , Spain

Medellin, , Colombia

Zagreb, , Croatia

Halifax, , Canada

Medellin, Antioquia, Colombia

Halle, Saxony Anhalt, Germany

Barranquilla, , Colombia

Rijeka, , Croatia

Udine, , Italy

London, , Canada

Karaganda, , Kazakhstan

Almaty, , Kazakhstan

Durango, , Mexico

Armenia, , Colombia

Cali, , Colombia

Medellin, , Colombia

Soledad, , Colombia

Ahmedabad, , India

Jaipur, , India

Rajkot, , India

Secunderabad, , India

Shymkent, , Kazakhstan

Gujarat, , India

Astana, , Kazakhstan

Summerville, South Carolina, United States

Floridablanca, , Colombia

Bekescsaba, , Hungary

Rājkot, , India

Semey, , Kazakhstan

Osijek, , Croatia

Poznan, , Poland

Sao Paulo, , Brazil

Toronto, Ontario, Canada

Woodbridge, Ontario, Canada

Kochi, Kerala, India

Pune, Maharashtra, India

Varanasi, Uttar Pradesh, India

Chennai, Tamil Nadu, India

Rome, , Italy

Queretaro, , Mexico

Santo Andre, Sao Paulo, , Brazil

Oaxaca, , Mexico

Brasilia, , Brazil

Santo Andre, , Brazil

Ferrol, , Spain

Tbilisi, , Georgia

Bydgoszcz, , Poland

Bydgoszcz, , Poland

Katowice, , Poland

Wroclaw, , Poland

Salzburg, , Austria

Prague, , Czechia

Szekesfehervar, , Hungary

Jaipur, Sardar Patel Marg, India

Tychy, , Poland

Johnson City, Tennessee, United States

Cedar Park, Texas, United States

San Marcos, Texas, United States

Innsbruck, Tyrol, Austria

Chicago, Il, Canada

Toronto, Ontario, Canada

London, , Canada

Medellín, Antioquia, Colombia

Armenia, , Colombia

Floridablanca, , Colombia

Medellin, , Colombia

Soledad, , Colombia

Rijeka, , Croatia

Virovitica, , Croatia

Brno, , Czechia

Praha 4, , Czechia

Pierre Benite, , France

Batumi, , Georgia

Berlin, , Germany

Berlin, , Germany

Duisburg, , Germany

Wipperfuerth, , Germany

Gyongyos, , Hungary

Chennai, Tamil Nadu, India

Ahmedabad, , India

Rajkot, , India

Negrar, Verona, Italy

Udine, , Italy

Almaty, , Kazakhstan

Astana, , Kazakhstan

Astana, , Kazakhstan

Shymkent, , Kazakhstan

Shymkent, , Kazakhstan

Queretaro, , Mexico

Durango, , Mexico

Bydgoszcz, , Poland

Czestochowa, , Poland

Krakow, , Poland

Krakow, , Poland

Poznan, , Poland

Warsaw, , Poland

Katowice, , Poland

Bucharest, , Romania

Bucharest, , Romania

Timisoara, , Romania

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported